Genome-wide association study (GWAS) approaches to cancer have been successful at identifying novel susceptibility loci, but there remains a fundamental gap in understanding the biological and clinical relevance of these discoveries. This problem is especially acute as there is an urgent need to translate basic scientific advancements into clinically relevant deliverables that will impact cancer patient care. The long-term goal of this research proposal is to discover the heritable component of neuroblastoma, an important childhood cancer that continues to result in significant morbidity and mortality, and to use this knowledge to develop novel therapeutic strategies. The primary objective of this competitive renewal application, based on the published and unpublished results from the first 4 years of funding, is to discover how host genetic architecture explains neuroblastoma susceptibility and patient survival, while also extending our initial findings that genes uncovered by our GWAS play a central role in tumor progression and maintenance. The central hypothesis to be explored here is that heritable DNA variation influences the initiation of neuroblastoma, the clinical course of the disease, and patient outcomes. This hypothesis builds on our identification of multiple common and rare DNA variations associated with neuroblastoma, the observation that many of the genes identified through these efforts impart oncogenic dependencies in established tumors, and the fact that recurrent somatic mutations are exceeding rare, even in the most aggressive subsets of this disease. The motivation for the proposed research is the urgent need to improve high-risk neuroblastoma survival rates and decrease treatment-related morbidities. We will test our central hypothesis in three specific aims: 1) Discover common and rare DNA variants that are associated with neuroblastoma;2) Identify the DNA polymorphisms that predict neuroblastoma patient survival;and 3) Determine how genes identified by the neuroblastoma GWAS act as oncogenic drivers of the malignant phenotype.
The first Aim will continue our discovery efforts by increasing the resolution of the scan and doubling the number of cases and controls, with the goal of delivering the identifiable heritable component of neuroblastoma.
Aim 2 is devoted to a GWAS within the neuroblastoma cases to define genetic determinants of patient survival, and this will build on our preliminary data identifying potential tumor cell intrinsic mechanisms of chemotherapy resistance via this approach.
The final Aim will determine the mechanism by which genes identified by the most robust association signals act as tumor suppressors or oncogenes in neuroblastoma cells, again building on our extensive preliminary data. We consider this project significant because it will define DNA variation, genes and pathways critical to neuroblastoma initiation and progression, and thus provide insights that will be actionable in the clinic and ultimately result in improved cure rates.
This research project is relevant to public health because the discovery of how common and rare DNA variation influence neuroblastoma susceptibility, patient outcomes and define oncogenic vulnerabilities in tumor cells will lead to more precise clinical biomarkers and therapies. The proposed research is highly relevant to the NIH mission and the urgent unmet need of developing rational evidence-based strategies to reduce the burden of cancer in general, and neuroblastoma in particular.
|Capasso, Mario; Diskin, Sharon; Cimmino, Flora et al. (2014) Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res 74:6913-24|
|Diskin, Sharon J; Capasso, Mario; Diamond, Maura et al. (2014) Rare variants in TP53 and susceptibility to neuroblastoma. J Natl Cancer Inst 106:dju047|
|Pugh, Trevor J; Morozova, Olena; Attiyeh, Edward F et al. (2013) The genetic landscape of high-risk neuroblastoma. Nat Genet 45:279-84|
|Bosse, Kristopher R; Diskin, Sharon J; Cole, Kristina A et al. (2012) Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res 72:2068-78|
|Latorre, Valeria; Diskin, Sharon J; Diamond, Maura A et al. (2012) Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans. Cancer Epidemiol Biomarkers Prev 21:658-63|
|Nguyen, Le B; Diskin, Sharon J; Capasso, Mario et al. (2011) Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet 7:e1002026|
|Wang, Kai; Diskin, Sharon J; Zhang, Haitao et al. (2011) Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469:216-20|
|Devoto, Marcella; Specchia, Claudia; Laudenslager, Marci et al. (2011) Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma. Hum Hered 71:135-9|
|Li, Hongzhe; Wei, Zhi; Maris, John (2010) A hidden Markov random field model for genome-wide association studies. Biostatistics 11:139-50|
|Mosse, Yael P; Wood, Andrew; Maris, John M (2009) Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 15:5609-14|
Showing the most recent 10 out of 16 publications